On August 18, PHARMARON rose 3.28% in regular trading, trading at 31.6 HKD/share, with turnover of 55.32 million HKD.

On the news front, the company's board of directors is scheduled to convene on August 20 to review and approve its first-half interim results. The company previously pre-announced H1 revenue of 7.472 billion to 7.665 billion yuan, representing year-over-year growth of 16%-19%. New signed orders grew over 30% year-over-year, with small molecule CDMO new orders surging more than 50%, indicating strong earnings visibility.

Meanwhile, the CXO sector continued its collective rally. Within the Life Sciences Tools and Services sector, GenScript Bio rose 6.9%, WuXi Bio gained 3.81%, and WuXi XDC advanced 3.62%, reflecting sustained industry recovery momentum driving sector-wide valuation repair.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)